Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs
Provided By GlobeNewswire
Last update: Dec 5, 2024
BERKELEY HEIGHTS, N.J., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it is in the process of exploring and reviewing strategic alternatives on an expedited basis in order to preserve the Company’s cash, including a potential transaction with investor David Lazar of Activist Investing, LLC, which transaction would be subject to the consent of an existing securityholder.
Read more at globenewswire.comNASDAQ:CYCC (7/15/2025, 10:22:30 AM)
11.24
+7.93 (+239.58%)
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP
NASDAQ:CYCCP (7/15/2025, 10:24:30 AM)
6.2
+1.29 (+26.27%)
Find more stocks in the Stock Screener
CYCC Latest News and Analysis
2 hours ago - ChartmillThese stocks are moving in today's pre-market sessionDiscover the top movers in Tuesday's pre-market session and stay informed about market dynamics.
18 hours ago - ChartmillGet insights into the top gainers and losers of Monday's after-hours session.As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
13 days ago - ChartmillTop movers in Wednesday's sessionStay up-to-date with the latest market trends one hour before the close of the markets on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
13 days ago - ChartmillThese stocks are moving in today's sessionCurious about what's happening in today's session? Check out the latest stock movements and price changes.
13 days ago - ChartmillGapping stocks in Wednesday's sessionLet's delve into the US markets on Wednesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
